

Continuing Education Credit Information

Course Description

This one-day symposium will provide an update on recent clinical advances in lung cancer. We have seen high impact advances in all aspects of lung cancer management, from detection to diagnosis and treatment. This symposium will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact didactic talks will be delivered by national thought leaders and well-respected faculty in each field. There will be updates on CT screening and smoking cessation, proper use of liquid biopsy, interpretation of molecular testing results and review of modern bronchoscopic interventions. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on proton beam radiation, minimally invasive surgery and immunotherapy as well as an introduction to oligometastatic cancer and its proper management. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over optimal management of metastatic, PD-L1 positive NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions and through a case-based format following each session with access to presentation materials for later review.

Learning Objectives

Physicians

- Explain the benefit of CT screening for lung cancer
- Discuss the current application of liquid biopsy (ctDNA analysis)
- Explain the role of multidisciplinary care for early-stage/locally advanced non-small cell lung cancer
- Discuss management options for patients with oligometastatic non-small cell lung cancer
- Discuss standard targeted agents in use for patients with driver-positive non-small cell lung cancer (including EGFR, ALK, ROS1, RET, NTRK, and MET)
- Describe the benefit of immunotherapy in the treatment of advanced small cell lung cancer
- Debate the controversies of immunotherapy alone or chemo-immunotherapy for PD-L1 positive non-small cell lung cancer
- Discuss management of immune-mediated toxicities

Nurses

- Explain the benefit of CT screening for lung cancer
- Discuss the current application of liquid biopsy (ctDNA analysis)
- Explain the role of multidisciplinary care for early-stage/locally advanced non-small cell lung cancer
- Identify nursing strategies for early detection of immune-mediated toxicities
- Cite unique toxicities associated with targeted agents used in NSCLC
- Recognize commune immune related adverse events and factors that increase patient risk

Pharmacists

- Discuss standard targeted agents in use for patients with driver-positive non-small cell lung cancer
- Discuss the role of multidisciplinary care for locally advanced non-small cell lung cancer
- Describe the benefit of immunotherapy in the treatment of advanced small cell lung cancer
- Understand the pharmacologic management of immune-mediated adverse events based on current guidelines and evidence

Target Audience

This conference is intended for pulmonologists, medical and radiation oncologists, pathologists, radiologists, nuclear medicine physicians, interventional radiologists, thoracic surgeons, residents, fellows, medical students, physician assistants, nurse practitioners, nurses, pharmacists, allied health professionals, and other members of the healthcare team interested in the diagnosis and treatment of lung cancer.

CE Accreditation



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation



This activity was planned by and for the healthcare team, and learners will receive 6.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Pharmacists

This curriculum has been approved for 6.5 contact hours by MedStar Health. MedStar Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The Universal Activity Number for this program is JA4008151-0000-19-026-L01-P. This learning activity is knowledge-based.

D.C. Lung Cancer Conference 2019

November 16, 2019 | Washington Marriott Wardman Park | Washington, D.C.

MedStar Health
3007 Tilden St., NW, Suite 3N
Washington, DC 20008

MedStar Georgetown
University Hospital
Lombardi Comprehensive
Cancer Center

For more information and to register, please visit
CE.MedStarHealth.org/Lung

D.C. Lung Cancer Conference 2019

November 16, 2019

Washington Marriott Wardman Park | Washington, D.C.

Course Directors

Stephen V. Liu, MD

MedStar Georgetown University Hospital
Washington, D.C.

Chul Kim, MD, MPH

MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Washington, D.C.

MedStar Georgetown
University Hospital
Lombardi Comprehensive
Cancer Center

#DCLUNG19

Course Directors

Stephen V. Liu, MD
Director, Thoracic Medical Oncology
Director, Phase I Developmental Therapeutics
MedStar Georgetown University Hospital
Associate Professor, Medicine
Georgetown University Medical Center
Washington, D.C.

Chul Kim, MD, MPH
Thoracic Medical Oncologist
MedStar Georgetown University Hospital
Assistant Professor, Medicine
Georgetown University Medical Center
Washington, D.C.

Faculty

Eric D. Anderson, MD
Director, Interventional Pulmonology
MedStar Georgetown University Hospital
Professor, Clinical Medicine
Georgetown University Medical Center
Washington, D.C.

Simona L. Armanca, PharmD, BCOP
Clinical Pharmacy Specialist
MedStar Georgetown University Hospital
Washington, D.C.

Joshua Bauml, MD
Assistant Professor, Medicine
Perelman School of Medicine at the
University of Pennsylvania
Philadelphia, PA

Hossein Borghaei, DO, MS
Chief, Thoracic Medical Oncology
Professor, Hematology and Oncology
The Gloria and Edmund M. Dunn Chair in
Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, PA

Alexander E. Drilon, MD
Clinical Director, Early Drug
Development Service
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Balazs Halmos, MD
Director, Thoracic/Head and Neck Oncology
Montefiore Medical Center
Professor, Medicine
Albert Einstein College of Medicine
Bronx, NY

Sushma Jonna, MD
Clinical Fellow
Hematology/Oncology
Georgetown Lombardi
Comprehensive Cancer Center
Washington, D.C.

Puja Gaur Khaitan, MD
Director, Esophageal Surgery
MedStar Washington Hospital Center
Associate Professor, Division of
Thoracic Surgery
Georgetown University Medical Center
Washington, D.C.

Hira Latif, MD
Chief Fellow, Hematology- Oncology
MedStar Washington Hospital Center
Washington, D.C.

John F. Lazar, MD
Director, Thoracic Robotic Surgery
Thoracic Surgeon
MedStar Washington Hospital Center
Assistant Professor, Medicine
Georgetown University Medical Center
Washington, D.C.

Benjamin P. Levy, MD
Clinical Director, Medical Oncology
Thoracic Medical Oncologist
Johns Hopkins Sidney Kimmel Cancer
Center at Sibley Memorial Hospital
Associate Professor, Oncology
Johns Hopkins University
School of Medicine
Washington, D.C.

Jessica J. Lin, MD
Medical Oncologist/Hematologist
Massachusetts General Hospital
Instructor, Medicine
Harvard Medical School
Boston, MA

Jonathan W. Lischalk, MD
Radiation Oncologist
MedStar Georgetown University Hospital
Assistant Professor, Medicine
Georgetown University Medical Center
Washington, D.C.

Marc Margolis, MD
Thoracic Surgeon
MedStar Georgetown University Hospital
Washington, D.C.

Eunice A. Ochuonyo MSN, FNP-C
Nurse Practitioner
MedStar Georgetown University Hospital
Washington, D.C.

Monica Peravali, MD
Medical Oncologist/Hematologist
MedStar Washington Hospital Center
Washington, D.C.

Michael T. Serzan, MD
Clinical Fellow
Hematology/Oncology
MedStar Georgetown University Hospital
Washington, D.C.

Irina G. Veytsman, MD
Section Director, Hematology/Oncology
Medical Oncologist/Hematologist
MedStar Washington Hospital Center
Washington, D.C.

Jessica S. Wang Memoli, MD
Pulmonary, Critical Care, and
Respiratory Services
MedStar Washington Hospital Center
Washington, D.C.

Agenda

8:00 a.m. Registration and Continental Breakfast

SESSION I: Diagnosing Lung Cancer in the Modern Era
Moderator: John F. Lazar, MD

9:10 a.m. Case Presentation
Hira Latif, MD

9:20 a.m. The Current Status of CT Screening
Eric D. Anderson, MD

9:40 a.m. The Evolving Role of Liquid Biopsy in Lung Cancer
Benjamin P. Levy, MD

10:00 a.m. Advances in Peripheral Lung Access & Bronchoscopic Interventions
Jessica S. Wang Memoli, MD

10:20 a.m. Panel Discussion

10:30 a.m. Break and Visit the Exhibits

SESSION II: Multidisciplinary Management of Locally Advanced Lung Cancer
Moderator: Puja G. Khaitan, MD

10:50 a.m. Case Presentation
Monica Peravali, MD

11:00 a.m. Proton Beam Radiation Therapy in Lung Cancer
Jonathan W. Lischalk, MD

11:20 a.m. Surgical Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Marc Margolis, MD

11:40 a.m. Immunotherapy in Resectable or Locally Advanced NSCLC
Chul Kim, MD, MPH

12:00 p.m. Managing Oligometastatic NSCLC
Joshua Bauml, MD

12:20 p.m. Panel Discussion

12:30 p.m. Lunch and Visit the Exhibits

SESSION III: Updates on Targeted Therapy in Lung Cancer
Moderator: Chul Kim, MD, MPH

1:30 p.m. Case Presentation
Sushma R. Jonna, MD

1:40 p.m. Sequencing Therapies in ALK Positive NSCLC
Jessica J. Lin, MD

2:00 p.m. Optimizing Care in EGFR Positive NSCLC
Irina Veytsman, MD

2:20 p.m. Evolving Targets Beyond EGFR and ALK
Alexander E. Drilon, MD

2:40 p.m. Panel Discussion

SESSION IV: Advances in Immunotherapy for Lung Cancer
Moderator: Stephen V. Liu, MD

2:50 p.m. Case Presentation
Michael T. Serzan, MD

3:00 p.m. Immunotherapy for Small Cell Lung Cancer
Stephen V. Liu, MD

3:20 p.m. Debate: Managing Advanced PDL1 Positive NSCLC – Monotherapy
Balazs Halmos, MD

3:40 p.m. Debate: Managing Advanced PDL1 Positive NSCLC – Chemo-Immunotherapy
Hossein Borghaei, DO, MS

4:00 p.m. Nursing Perspectives in the Mangement of Immunotherapy
Simona Armanca, PharmD, BCOP;
Eunice A. Ochuonyo MSN, FNP-C

4:20 p.m. Panel Discussion and Challenging Cases

4:45 p.m. Closing Remarks

Registration Information

Registration Fees:	
Physician	\$175
Resident or Fellow	\$100
Physician Assistant	\$100
Nurse Practitioner	\$100
Nurse	\$100
Pharmacist	\$100
Allied Health Professional	\$100

Online Registration Preferred

Please visit our secure website at [CE.MedStarHealth.org/Lung](https://ce.medstarhealth.org/Lung) for updated program and registration information. We are unable to accept registrations or cancellations by telephone. If you wish to pay your registration fee by check, please download and print a registration form and mail it to the address on the registration form with your check.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at MedStarCME@gmail.com or 202-735-3104.

Cancellation Policy

Cancellations made in writing by October 16, 2019 will be subject to a 50% penalty. No refunds will be given after this date. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Please call 202-735-3104 or email MedStarCME@gmail.com if you have any questions or need any additional information.

Venue Information

Washington Marriott Wardman Park
2660 Woodley Road, NW
Washington, D.C. 20008
202-328-2000
<https://wardmanparkmarriott.com>

A block of rooms has been reserved for attendees at the hotel at the discounted rate of \$139 per night (exclusive of taxes and fees). Reserve your room by October 25 to take advantage of this rate. Reservations can be made by calling 1-877-212-5752 or online at <http://bit.ly/LungWP>

Special Assistance

MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact 202-735-3104 to notify us of your needs.

